Heferol

Quick links to important sections

Heferol

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Heferol

Property Description
Active Ingredient Ferrous Fumarate (Iron(II) fumarate)
Form Oral Capsule or Tablet
Pharmacological Class Anti-anemic Preparation / Hematinic
General Purpose Correcting or preventing iron deficiency
Origin Synthetic Compound (Salt of an essential mineral)

What Type of Medicine is Heferol (Ferrous Fumarate)?

Heferol is an anti-anemic preparation and a hematinic, belonging to the class of Iron Products used to address mineral deficiency. The active substance, Ferrous Fumarate, is chemically classified under the Anatomical Therapeutic Chemical (ATC) code B03AA02 for iron bivalent, oral preparations. This places it among the essential mineral supplements relied upon in clinical practice to restore adequate iron stores. Clinical guidelines widely support the use of oral iron salts like Ferrous Fumarate as a recognized means of supplementation.

Composition and Pharmaceutical Form

The active ingredient in Heferol is Ferrous Fumarate, a synthesized organic iron salt that serves as the therapeutic source of bioavailable elemental iron. The compound is a specific salt of iron and fumaric acid. Heferol is differentiated within the market by often being formulated as an oral capsule for convenient ingestion, contrasting with liquid or chewable forms of other iron supplements. This specific presentation ensures the delivery of a consistent and measured quantity of the active substance.

General Purpose: Why is Heferol Used?

The general purpose of Heferol is to provide the necessary iron required to correct or prevent low iron levels in the body, a condition often recognized in populations with increased needs. Iron is fundamentally required for the efficient synthesis of hemoglobin, the protein within red blood cells crucial for oxygen transport. By supplying the mineral, the preparation helps ensure that the circulating blood can maintain adequate oxygen-carrying capacity to all vital organs and tissues.

What side effects are possible with Heferol?

Possible Side Effects and Safety Information

This information describes the documented safety profile of Heferol (Ferric Maltol), strictly based on official regulatory sources (e.g., FDA, EMA). It does not contain dosing instructions, therapeutic uses, or medical advice.


Adverse Reactions

The most common adverse reactions are related to the Gastrointestinal System and are typically mild to moderate. These effects are classified as Common (occurring in 1% of patients) and may include:

  • Flatulence
  • Diarrhea
  • Constipation
  • Abdominal pain or discomfort
  • Nausea and Vomiting
  • Feces discolored (black or dark stools)

Other less common adverse reactions may affect the Nervous System, Skin, or result in general physical discomfort.


Serious Safety Restrictions (Contraindications and Warnings)

Heferol must not be used if a patient has specific pre-existing conditions, which are known as Contraindications:

  • A known history of hypersensitivity to Ferric Maltol or any of its components.
  • Any condition involving iron overload, such as hemochromatosis.
  • Patients who are receiving repeated blood transfusions.

Warnings and Precautions require attention and monitoring, including the need to avoid use during an active flare-up of Inflammatory Bowel Disease (IBD) due to the potential for increased gastrointestinal inflammation. Treatment requires monitoring of iron parameters before and during therapy to manage the risk of iatrogenic iron overload.


Population-Specific Safety Notes

  • Pregnancy: The drug may be considered if necessary, as systemic absorption of the ferric maltol complex is negligible, but untreated iron deficiency anemia is associated with known maternal and fetal risks.
  • Pediatric Use: Safety and efficacy have not been established in children.

Overdose and Emergency Response

Overdose and When to Seek Help

Accidental overdose of iron-containing products, such as Heferol (Ferrous Fumarate), is documented in regulatory warnings as a leading cause of fatal poisoning in children under 6. Due to this severe risk and the potential for rapid progression, immediate medical attention is required for any suspected overdose event. It is mandatory to keep this product strictly out of the reach of children.

Manifestations and Severity

Overdose may present as a multi-stage clinical syndrome. Initial manifestations include severe Gastrointestinal (GI) toxicity, such as abdominal pain, vomiting (which may be bloody), and bloody diarrhea. These early signs may be followed by a quiescent phase before the onset of dangerous systemic toxicity, characterized by lethargy, low blood pressure (hypotension), metabolic acidosis, and shock. The officially documented severe outcomes include multi-organ failure, acute hepatic necrosis (liver damage), and cardiovascular collapse. Hospital evaluation is required for ingestions mathbfgeq 40 mg/ kg of elemental iron.

Emergency Actions

If an overdose is suspected, seek immediate medical attention or call a doctor/Poison Control Center immediately. Management of systemic toxicity involves procedures described in official regulatory texts. A specific antidote, the chelating agent Desferrioxamine, is utilized to manage the systemic effects of iron poisoning. Other supportive measures include intravenous fluid resuscitation, Whole Bowel Irrigation (WBI), and continuous monitoring of vital signs and serum iron concentrations.

Therapeutic Uses of Heferol

What Heferol treats: main uses and benefits

Heferol (Ferrous Fumarate) is commonly used to help manage low iron levels in the body, which can lead to Iron Deficiency Anemia (IDA). Iron supplements are generally applied when dietary intake may be insufficient to support the body's needs. The core therapeutic benefit is that this medication is relevant for easing symptoms that create noticeable physiological strain.

Therapeutic Scope and Key Benefits

Heferol is applied across domains where additional symptomatic support is needed to address the quantitative lack of iron. The medication is commonly used for managing symptom clusters that may become intense or disruptive, such as chronic fatigue, weakness, and low physical stamina. It is also applied in clinical settings where supportive symptom management is appropriate for conditions marked by increased physiological stress, such as in pregnancy or during periods of rapid growth.

Brief listing of indications: This medication is used for managing Iron Deficiency Anemia, latent iron deficiency, and supporting iron needs in situations of chronic blood loss or high demand like pregnancy.

“It is relevant for managing symptom clusters that may become intense or disruptive, helping patients cope more steadily with difficult episodes of fatigue and shortness of breath upon exertion.”

Quick Fact: Relief for Chronic Energy Depletion The primary benefit in day-to-day life is providing support that helps ease the overall symptom burden, which assists with maintaining functional stability and general well-being.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Eligibility Rules for Heferol (Ferrous Fumarate)

The population eligibility for using this medicine is strictly defined by regulatory authorities, focusing on preventing iron overdose and managing existing health conditions.

Eligibility Scope Status as Stated in Official Labeling
Populations for whom use is allowed Established for adults and older adults for treatment and prevention of iron deficiency states.
Pregnancy and Lactation May be used during pregnancy and breast-feeding when clinically indicated by a healthcare professional.
Populations for whom use is contraindicated Absolute contraindications include Hypersensitivity to ferrous fumarate, iron overload conditions (such as haemochromatosis), and anaemias not caused by iron deficiency (e.g., hemolytic anemia).
Condition-specific rules Contraindicated in patients with active gastrointestinal disease, including peptic ulcer, ulcerative colitis, or regional enteritis. Use requires caution in those with a history of controlled peptic ulceration.
Age-related rules The capsule or tablet formulation is not recommended for the treatment of children; alternative liquid formulations are generally advised by regulators for this population.

The eligibility profile is strictly defined by Absolute Contraindications to prevent toxicity in individuals with excess iron stores or those receiving repeated blood transfusions. Use is also prohibited in the presence of severe, active gastrointestinal inflammation. The medicine is deemed eligible for adults and for managing iron needs during pregnancy and lactation when medically necessary.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Ferrous Fumarate (Heferol) is primarily defined by the physicochemical effects of iron cations in the gastrointestinal tract, which can impact the absorption of both the iron product and co-administered medicines. The official documentation identifies several key interaction domains, necessitating specific administration constraints.


Documented Interaction Domains and Implications

Interacting Product Category Example Medicines Interaction Mechanism Practical Implication
Antacids and pH-Modifying Agents Aluminum/Magnesium salts, Proton Pump Inhibitors (PPIs) Decrease gastric acidity Reduced absorption of Ferrous Fumarate
Antibiotics Tetracyclines, Quinolones (e.g., Ciprofloxacin) Chelation of iron in the GI tract Reduced absorption of both the antibiotic and the iron
Dopaminergic Agents Levodopa, Carbidopa Iron decreases absorption Reduced efficacy of the dopaminergic agent
Thyroid Preparations Levothyroxine Iron decreases absorption Reduced efficacy of the thyroid preparation
Other Cation Binders Bisphosphonates, Calcium/Zinc Supplements Chelation and competitive binding Reduced absorption of both the iron and the co-administered agent

Administration Constraints

To manage these clinically significant interactions, regulatory sources emphasize the requirement for timing separation. For many of the listed interacting medicines, including quinolones, tetracyclines, and L-dopa, Ferrous Fumarate must be administered at least two hours before or six hours after the co-administered product to mitigate reduced systemic exposure. Oral iron may also need to be suspended for at least five days prior to colonoscopy as it can interfere with mucosal visualization.

Mechanism of Action

How Heferol Works: Iron Supplementation Mechanism

Heferol (ferrous fumarate) acts by introducing ferrous iron ( Fe^2+) into the system, which is the required substrate for several critical biological pathways. The mechanism operates across three core domains: intestinal uptake, systemic transport, and cellular utilization.

Iron Absorption and Entry into Circulation

This domain describes the initial step where the Fe^2+ form is actively transported across the duodenal mucosal barrier via specific carrier proteins, such as DMT1 (Divalent Metal Transporter 1). This uptake mechanism facilitates the augmentation of the systemic iron pool, thereby regulating the body's overall iron availability.

Transport and Delivery to Synthesis Sites

This refers to the phase where absorbed iron binds to the circulating protein transferrin, which delivers it to sites of high demand, principally the bone marrow. This transport pathway functions as the raw material for major biosynthetic cascades that require iron.

Iron Utilization in Hemoglobin Synthesis

The final domain involves the iron being incorporated into the protoporphyrin ring to form heme, which then combines to create hemoglobin within developing red blood cells. This mechanistic cascade is critical for increasing the potential for hemoglobin synthesis, which determines the oxygen-carrying function of blood, resulting in the incorporation of iron into hemoglobin, thereby altering the physiological capacity for oxygen transport.

Dosage and Administration Information

How to Use Heferol — Official Administration Guidelines

Heferol is an oral medication, typically supplied as a capsule, that must be administered following a specific schedule and method as defined in the regulatory documents.

Dosage and Frequency

Context Elemental Iron Dose Administration Frequency
Prophylaxis (Prevention) 50 mg Once per day
Treatment 100 mg to 200 mg Divided into 1 to 3 times per day

Dosage for pediatric use is generally weight-based, often 3 to 6 mg elemental iron per kg of body weight daily, divided into 1 to 3 doses. Use in all patients must be individualized based on the specific context.


Administration Procedure

  1. Swallow the capsule whole with a drink of water. The capsule must not be opened, broken, chewed, or sucked, due to the risk of mouth ulceration and tooth discoloration.
  2. Timing relative to meals is critical for absorption. For best results, take the dose 30 minutes before or 2 hours after a meal. However, if the medicine causes stomach upset, it may be taken with or immediately after food.
  3. Avoid consuming milk, coffee, tea, and eggs around the time of dosing, as these can interfere with iron absorption.

Missed Dose Instructions

If a dose is missed, skip the missed dose and continue with the next scheduled dose at the regular time. Do not take two doses at the same time to make up for a missed one.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Heferol

This overview describes the research landscape for oral iron salts, specifically Ferrous Fumarate, as reported in scientific literature and referenced by regulatory bodies. It focuses on what types of studies exist, what measurements were taken, and where the evidence is still developing.


Evidence for Addressing Iron Deficiency Anemia (IDA)

A significant portion of the evidence for oral iron salts is found in Randomized Controlled Trials (RCTs) and comprehensive scientific reviews. These studies primarily focus on adults diagnosed with IDA. Research has examined populations with conditions characterized by functional limitations, with studies monitoring outcomes related to systemic or functional imbalance. The studies monitored changes in key blood parameters, specifically Hemoglobin levels and the repletion of iron stores (measured by serum ferritin).

Studies describe patterns of biomarker measurement over defined time intervals, often observing shifts within 4 to 12 weeks. Research also explored patient-reported outcomes describing perceived discomfort, with some trials monitoring patterns related to fatigue or low physical stamina. While the data for changes in blood biomarkers is well-established, there is limited information for long-term outcomes regarding sustained patient experience or functional stability.


Research in Special Populations

Research exploring iron supplementation during pregnancy consists of many clinical trials and systematic reviews. These studies were evaluated in expectant mothers, tracking maternal iron status and specific neonatal outcomes. Research explored whether supplementing with iron was associated with differences in the frequency of measured low hemoglobin levels at term when compared to control groups.

Evidence for older adults with IDA is often derived from smaller trials and aggregated analyses, as few dedicated, large-scale RCTs exist for this group. The research describes patterns observed in these studies, where changes in Hemoglobin were measured over a short observation course. Data for certain functional outcomes in this population remain insufficient.


Research Gaps and Areas of Uncertainty

The majority of clinical trials focus on short- to intermediate-term follow-up, typically lasting up to 6 months. Long-term effects are not fully established through primary RCTs, and data for long-term outcomes remain insufficient. A primary limitation is the focus on biomarkers (Hb, ferritin) over detailed, long-term patient-focused outcomes (quality of life, sustained functional improvement). The results apply only to the populations studied, meaning subgroup findings are uncertain for specific, complex patient groups.

Key Studies & References

  1. A randomized controlled trial of thrice-weekly versus thrice-daily oral ferrous fumarate treatment in adult patients with iron-deficiency anemia (RCT)

Frequently Asked Questions (FAQ)

Common questions about Heferol (FAQ)

Q: Do studies support the use of Heferol for long-term health?

Studies on oral iron preparations, including Heferol, primarily focus on short- to intermediate-term follow-up, typically up to six months. Official documents state that long-term effects and sustained patient-focused outcomes beyond this period are not fully established through primary clinical trials.

Q: Does Heferol interact with any vitamins, like Vitamin C or B12?

The absorption of iron is often enhanced by Vitamin C (ascorbic acid). Official sources do not typically indicate a direct interaction with Vitamin B12 (cyanocobalamin). If the product is a combination preparation, patients are generally advised to consult the specific prescribing information.

Q: Do the official documents mention any serious but rare side effects of Heferol?

Official documents outline rare but serious side effects reported with iron products, which may include signs of a severe allergic reaction (such as swelling or difficulty breathing) or signs of internal bleeding (like bloody or tarry stools). Should any severe symptoms occur, official guidance suggests seeking prompt medical attention.

Q: Can Heferol affect the results of certain medical tests?

Yes, Heferol and other oral iron products can interfere with certain laboratory procedures. For example, iron can cause false positive results on tests used to check for blood in the stools (fecal occult blood tests).

Q: Are there any known long-term side effects noted in official documentation?

While long-term safety data are limited, official documentation highlights the risk of iron overload (hemosiderosis) with prolonged or excessive use. This risk is particularly noted for individuals who are genetically predisposed to storing too much iron.

Q: Does official evidence indicate Heferol is generally well-tolerated?

Official evidence confirms that Heferol is generally associated with common gastrointestinal adverse reactions such as flatulence, constipation, diarrhea, and stomach discomfort. These effects are typically mild to moderate, and official information notes that some effects may lessen over time.

Q: What are the guidelines regarding taking Heferol before or after surgery?

Regulatory guidance specifically addresses the need to suspend oral iron prior to certain procedures, such as a colonoscopy, due to potential interference with the examination. For general surgery, official patient information suggests that individuals inform the doctor or dentist that they are taking the iron product.

Q: What is the significance of the research evidence theme for Heferol?

The research evidence indicates that oral iron salts are a studied approach in the correction of iron deficiency anemia (IDA). This is primarily confirmed by the ability of the drug to be associated with changes in key blood parameters, such as Hemoglobin and replenished iron stores, over the short to intermediate term.

Q: What is the reason Heferol requires a doctor's decision for use?

Medical oversight is required primarily to rule out conditions where iron is contraindicated (like hemochromatosis or non-iron deficiency anemia), manage the high risk of fatal iron overdose in children, and monitor iron parameters to prevent iatrogenic iron overload.

Q: Is Heferol the same as a regular iron supplement?

Heferol is classified as an anti-anemic preparation (a hematinic) containing the specific active ingredient Ferrous Fumarate. It is a bivalent iron salt and falls within the general class of mineral supplements, often regulated as a prescription-strength or high-dose iron product.

Q: Can people with kidney concerns generally use Heferol?

Ferrous Fumarate is frequently studied in the context of iron deficiency anemia in adults who have chronic kidney disease (CKD). However, the management of treatment and iron levels for individuals with kidney concerns is generally managed with close monitoring by a healthcare provider.

Q: Does Heferol have interactions with common over-the-counter pain relievers?

Official documents list interactions with several drug categories but do not typically single out common over-the-counter pain relievers (like NSAIDs or acetaminophen). Official information indicates that patients are often encouraged to disclose all prescription and non-prescription medicines, including OTC pain relievers, to a healthcare provider.

Q: Why might a person need to stop using Heferol after a certain period?

Regulatory and clinical guidance indicates that the medicine should be discontinued once the iron stores (ferritin) are replenished and within the normal range. Use is also typically avoided during an active flare-up of Inflammatory Bowel Disease (IBD) due to the potential for increased gastrointestinal inflammation.

Q: Is Heferol available without a prescription in some regions?

Products containing Ferrous Fumarate may be available as both prescription-only medications and as over-the-counter dietary supplements in various strengths. The legal status of the specific Heferol formulation depends on the regulatory decisions of the region.

Q: What is the general safety classification of Heferol by regulatory bodies?

Ferrous Fumarate is classified within the Iron Products drug class (a mineral supplement). Regarding use in pregnancy, it is often categorized as a Pregnancy Category C agent by some regulatory bodies, meaning the risk to the fetus cannot be definitively ruled out.

Q: Does Heferol have any recognized sedative or stimulating properties?

Official lists of common and serious adverse reactions for ferrous fumarate do not include central nervous system (CNS) effects such as sedation or stimulation as expected side effects.

Q: Can Heferol interact with herbal supplements?

Official patient information generally suggests that individuals consult with a healthcare professional before taking any herbal remedies or supplements with Heferol, as potential interactions or additive effects are possible.

Q: How does Heferol's action differ from dietary iron intake?

Heferol is formulated to provide elemental iron that is absorbable by the body, offering a measured amount of the active ingredient for supplementation.

Q: Does Heferol affect blood sugar levels, according to research?

Research and safety information do not indicate that Heferol significantly alters blood sugar levels. However, caution is advised for patients who have diabetes due to the potential content of inactive ingredients (excipients) in certain formulations.

Q: Can Heferol be used by people who follow a vegetarian or vegan diet?

The active ingredient, Ferrous Fumarate, is a synthesized inorganic salt. However, determining the final product's suitability for vegetarian or vegan diets depends on the specific excipients and capsule shell material, which is information found on the individual product label.

Q: How long does Heferol stay in the body's system generally?

The body primarily regulates iron by controlling how much is absorbed, as excretion is limited. The iron from Heferol is absorbed and incorporated into the body’s essential iron pool (such as in hemoglobin and ferritin stores), where it remains until it is utilized, rather than being rapidly eliminated.

Q: Are there official statements regarding the maximum duration of use for Heferol?

Official treatment guidelines typically recommend continuing the use until the iron deficiency is corrected and iron stores are replenished. This duration is generally recommended for a period determined by the time required to correct deficiency, or until the serum ferritin levels are within the normal range.

Q: Does Heferol cause weight gain or loss, based on official information?

Weight gain or weight loss is not listed as a common or serious adverse reaction in the official documentation for the active ingredient, ferrous fumarate.

Q: What are the potential interactions between Heferol and heart medicines?

Regulatory documents list interactions with certain drug classes, such as thyroid preparations and specific antibiotics. Official information generally suggests that individuals confirm all co-administered cardiac medicines with a healthcare provider, as the documented interactions list may not be exhaustive.

Q: Can Heferol affect sleep patterns or cause insomnia?

Official adverse reaction lists for ferrous fumarate do not commonly include central nervous system (CNS) effects such as insomnia or other sleep disturbances as expected side effects.

How should Heferol be stored and disposed of?

How to Store and Dispose of Heferol?

Regulatory agencies mandate specific rules for storing and discarding Heferol (Ferrous Fumarate) to maintain stability and ensure safety.

Official Storage Requirements

Constraint Requirement
Temperature Store at controlled room temperature, typically below 25 C or 30 C (59 F to 86 F).
Protection Keep in the original container, tightly closed, and protect from light and excessive moisture.
Safety Keep out of the sight and reach of children in a child-resistant container, as accidental overdose of iron products is severely toxic.
Stability Do not use the medication after the Expiration Date printed on the packaging.

Disposal Instructions

Do not throw away Heferol via wastewater or regular household trash. For safe disposal of unused or expired medicine, consult a pharmacist or follow the instructions provided by local waste collection regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Heferol found in:

A-Z Index: